Unexpected responses to EGFR inhibition in NSCLC
The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identifies a distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demonstrated that EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are superior to stand...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2015-01-01
|
| Серии: | Respiratory Medicine Case Reports |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2213007115300113 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|